Skip to content
2000
Volume 3, Issue 2
  • ISSN: 1872-2148
  • E-ISSN: 2212-3334

Abstract

Much interest has focused on the newer incretin-based therapeutic modalities for diabetes, especially GLP-1 analogues. While the comparatively older GLP-1 analogs, exenatide and liraglutide, have been discussed extensively in literature, much less is known about the newer GLP-1 analogues in the pipeline. This review focuses on the newer molecules being studied, the newer routes of administration being tried, some recent patents and potential uses for these multifaceted compounds.

Loading

Article metrics loading...

/content/journals/emi/10.2174/187221409788452309
2009-06-01
2025-10-01
Loading full text...

Full text loading...

/content/journals/emi/10.2174/187221409788452309
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test